Jani AB - Search Results

1

A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.

Terakedis BE, Rossi PJ, Liauw SL, Johnstone PA, Jani AB. Terakedis BE, et al. Among authors: jani ab. Am J Clin Oncol. 2010 Dec;33(6):619-23. doi: 10.1097/COC.0b013e3181c4c6e1. Am J Clin Oncol. 2010. PMID: 20051808

2

PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention.

Jani AB, Chen MH, Vaida F, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. Jani AB, et al. Urology. 1999 Oct;54(4):700-5. doi: 10.1016/s0090-4295(99)00229-0. Urology. 1999. PMID: 10510931

3

Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience.

Connell PP, Ignacio L, Haraf D, Awan AM, Halpern H, Abdalla I, Nautiyal J, Jani AB, Weichselbaum RR, Vijayakumar S. Connell PP, et al. Among authors: jani ab. J Clin Oncol. 2001 Jan 1;19(1):54-61. doi: 10.1200/JCO.2001.19.1.54. J Clin Oncol. 2001. PMID: 11134195

4

Analysis of the role of adjuvant chemotherapy for invasive carcinoma of the esophagus.

Jani AB, Connell PP, Vesich VJ, O'Brien KM, Chen LM. Jani AB, et al. Am J Clin Oncol. 2000 Dec;23(6):554-8. doi: 10.1097/00000421-200012000-00003. Am J Clin Oncol. 2000. PMID: 11202794

5

Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.

Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M 3rd, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. Jani AB, et al. Int J Cancer. 2001 Dec 20;96(6):363-71. doi: 10.1002/ijc.1035. Int J Cancer. 2001. PMID: 11745507

6

Early prostate cancer: clinical decision-making.

Jani AB, Hellman S. Jani AB, et al. Lancet. 2003 Mar 22;361(9362):1045-53. doi: 10.1016/S0140-6736(03)12833-4. Lancet. 2003. PMID: 12660074 Review.

7

Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.

Jani AB, Basu A, Abdalla I, Connell PP, Krauz L, Vijayakumar S. Jani AB, et al. Am J Clin Oncol. 2003 Aug;26(4):382-5. doi: 10.1097/01.COC.0000026483.80660.94. Am J Clin Oncol. 2003. PMID: 12902891

8

Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans.

Jani AB, Hand CM, Lujan AE, Roeske JC, Zagaja GP, Vijayakumar S, Pelizzari CA. Jani AB, et al. Med Dosim. 2004 Spring;29(1):42-8. doi: 10.1016/j.meddos.2003.09.005. Med Dosim. 2004. PMID: 15023392

9

Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy.

Jani AB, Al-Qamari A, Sapra B, Krauz L, Awan A, Kocherginsky M, Gillen D. Jani AB, et al. Clin Prostate Cancer. 2004 Jun;3(1):43-8. doi: 10.3816/cgc.2004.n.012. Clin Prostate Cancer. 2004. PMID: 15279690

10

Impact on late toxicity of using transabdominal ultrasound for prostate cancer patients treated with intensity modulated radiotherapy.

Jani AB, Gratzle J, Muresan E, Martel MK. Jani AB, et al. Technol Cancer Res Treat. 2005 Feb;4(1):115-20. doi: 10.1177/153303460500400115. Technol Cancer Res Treat. 2005. PMID: 15649095 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

237 results

Search Page

Filters